Search Clinical Trials | Froedtert & MCW

Keyword

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

38 results for "Cancer" and "Head and Neck Cancers"

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer

Durvalumab Following SBRT for the Treatment of Patients with Stage I/II NSCLC

Protocol No

AZ-D9103C00001-PACIFIC-4

Sub Category

Thoracic Cancers

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

Durvalumab or Durvalumab and Tremelimumab for Patients with Stage I-III LLimited Disease SCLC

Protocol No

AZ-D933QC00001-ADRIATIC

Sub Category

Thoracic Cancers

Randomized, open label Phase 3 study of SAR408701 versus Docetaxel in previously treated metastatic non-squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors

Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic Non-Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors (CARMEN-LC03)

Protocol No

SANOFI-EFC15858

Sub Category

Thoracic Cancers

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Testing the Addition of an Antibody toStandard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients
With Unresectable Stage III Non-Small Cell Lung Cancer

Protocol No

ECOG-EA5181

Sub Category

Thoracic Cancers

A Phase I Study of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients with Head and Neck Cancer

Protocol No

IIT-AWAN-NIH-DEHART

Sub Category

Head and Neck Cancers

A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Protocol No

RTOG-1008

Sub Category

Head and Neck Cancers

A Topical Antiseptic Bundle for Decreasing Surgical Site Infection after Head Neck Cancer Surgery: Peri-operative Effects on the Oral Microbiome

Topical Antisepsis in Head and Neck Cancer Surgery

Protocol No

IIT-ZENGA-ANTISEPSIS

Sub Category

Head and Neck Cancers

A Phase I/II Study of TheraT^® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers

This study is to investigate the study drug in patients with a specific type of cancer called human papillomavirus 16-positive (HPV 16+) cancers. HPV 16+ cancers include head and neck, cervical, anal, vaginal, vulvar, and penile cancers. The main goal of the study is to determine whether HB-201 and HB-202 are effective in the treatment of human papillomavirus 16 positive (HPV 16+) confirmed cancers.

Protocol No

HOOKIPA-H-200-001

Sub Category

Gynecologic Cancers

Early Phase/Multiple Disease Site Cancers

Head and Neck Cancers

A Phase 1 Study to Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Lorlatinib In Advanced Cancer Patients

This is a phase 1 study in advanced cancer patients with varied hepatic fucntions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.

Protocol No

PFIZER-B7461009

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers

Gastrointestinal Cancers

Endocrine Cancers

Breast Cancers

Randomized Phase II/III trial of adjuvant radiation therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in pathologic high-risk Squamous Cell Cancer of the head and neck

The purpose of this part of this study is to compare the effects, good and/or bad, of the standard treatment (radiation therapy and cisplatin) with one of the experimental treatments chosen from the first part of the study (either radiation therapy and docetaxel or radiation therapy, cetuximab, and docetaxel) to find out which is better.

Protocol No

RTOG-1216

Sub Category

Head and Neck Cancers

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST chemo-IO

Testing the addition of a type of drug called immunotherapy to the usual chemotherapy treatment for non-small cell lung cancer

Protocol No

ALLIANCE-ALCHEMIST-A081801

Sub Category

Thoracic Cancers

A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA

This study is being done to answer the following question: Does maintenance nivolumab following definitive therapy with radiation and chemotherapy (cisplatin) result in significant improvement in overall survival (OS) (time being alive) and progression-free survival (PFS) (time being alive without cancer) for patients with your type of cancer (intermediate risk HPV positive oropharynx cancer). We are doing this study because we want to find out if this approach is better or worse than the usual approach for your HPV positive oropharynx cancer. The usual approach is defined as care most people ...

Protocol No

ECOG-EA3161

Sub Category

Head and Neck Cancers

Establishment Of A National Biorepository To Advance Studies Of Immune-Related Adverse Events

This study is being done to answer the following questions: Why do some patients experience serious side effects from immunotherapies, and why do other patients not experience these side effects? How can we identify these patients and prevent, reduce and treat these side effects more effectively? To answer these questions, it is helpful to have clinical data and samples collected from patients who have experienced these side effects from immunotherapy. For example, by studying blood samples collected before and after side effects occur, researchers can look for markers that may predict ...

Protocol No

ALLIANCE-A151804

Sub Category

Gastrointestinal Cancers

Early Phase/Multiple Disease Site Cancers

Thoracic Cancers

Skin Cancers

Prostate and Urologic Cancers

Head and Neck Cancers

A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

Protocol No

BERGENBIO-BGB324

Sub Category

Thoracic Cancers

A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer

Testing the Use of Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer

Protocol No

SWOG-LUNGMAP-S1900B

Sub Category

Thoracic Cancers

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies

Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility

Protocol No

ADP-0000-001-SCR

Sub Category

Gynecologic Cancers

Prostate and Urologic Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Head and Neck Cancers

Gastrointestinal Cancers

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation to the usual whole-brain radiation. The hippocampus is part of the brain that is important for memory. Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It also is possible that avoiding the hippocampus could have no benefit or could cause other side effects. Hippocampal avoidance also could lessen the effectiveness of whole-brain radiation. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the addition of the hippocampal avoidance technique to whole-brain radiation therapy should decrease the chance of side effects on memory or thinking by at least 14.5%.

Protocol No

NRG-CC003

Sub Category

Brain and Spine Cancers

Thoracic Cancers

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for NSNSCLC

Protocol No

NRG-LU003

Sub Category

Thoracic Cancers

Phase II Randomized Trial Of Neo-Adjuvant Chemotherapy Followed By Surgery And Post-Operative Radiation Versus Surgery And Post-Operative Radiation For Organ Preservation Of T3 And T4a Nasal And Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

Testing the Addition of Chemotherapy to the Treatment of Cancer of the Sinonasal Area

Protocol No

ECOG-EA3163

Sub Category

Head and Neck Cancers

KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA) Plus Stereotactic Re-Irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Cancer

SBRT +/- Pembrolizumab in Patients w/ Local-Regionally Recurrent or 2nd Primary Head and Neck Cancer

Protocol No

RTOG-3507

Sub Category

Head and Neck Cancers

A Phase 1 Dose Escalation Study to Assess Safety and Efficacy of ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors

ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors

Protocol No

ADP-0055-001-MAGE-A4-SURPASS

Sub Category

Gastrointestinal Cancers

Skin Cancers

Thoracic Cancers

Sarcoma

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers